CLINICAL TRIALS PROFILE FOR RHINOCORT

505(b)(2) Clinical Trials for RHINOCORT

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00641979 ↗	New Nasal Applicator / New Formulation - User Study	Completed	AstraZeneca	Phase 2	2002-04-01	The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of seasonal allergic rhinitis (SAR).
OTC	NCT06076304 ↗	Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis	Active, not recruiting	Medstar Health Research Institute	Phase 4	2023-11-21	Sinus infections are sometimes treated with antibiotics or nasal sprays, while some patients get better on their own. Some patients may wait a few days or use common over-the-counter remedies to see if their symptoms improve without further treatment. The overall goal of this clinical trial to see which patients with sinus infections are more likely to respond to different treatments, and which improve with supportive care alone.
OTC	NCT06076304 ↗	Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis	Active, not recruiting	Patient-Centered Outcomes Research Institute	Phase 4	2023-11-21	Sinus infections are sometimes treated with antibiotics or nasal sprays, while some patients get better on their own. Some patients may wait a few days or use common over-the-counter remedies to see if their symptoms improve without further treatment. The overall goal of this clinical trial to see which patients with sinus infections are more likely to respond to different treatments, and which improve with supportive care alone.
OTC	NCT06076304 ↗	Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis	Active, not recruiting	Penn State College of Medicine	Phase 4	2023-11-21	Sinus infections are sometimes treated with antibiotics or nasal sprays, while some patients get better on their own. Some patients may wait a few days or use common over-the-counter remedies to see if their symptoms improve without further treatment. The overall goal of this clinical trial to see which patients with sinus infections are more likely to respond to different treatments, and which improve with supportive care alone.

All Clinical Trials for RHINOCORT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00560586 ↗	Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome	Completed	University of Louisville	Phase 4	2004-04-01	-Intranasal budesonide therapy may lead to improved symptoms and sleep study findings in children with mild obstructive sleep apnea with and without allergic rhinitis that would not be treated with T&A. The aim of the study is to conduct a randomized double blind cross-over trial comparing the effect of once a day intranasal budesonide therapy vs. placebo in children with mild sleep apnea that would not be candidates for T&A.
NCT00641212 ↗	Children, Perennial Allergic Rhinitis (PAR), l-t Growth	Completed	AstraZeneca	Phase 4	2000-01-01	The purpose of this study is to compare the effect of Rhinocort nasal spray with placebo on growth in children with perennial allergic rhinitis over 12 months.
NCT00641680 ↗	Rhinocort Aqua Versus Placebo and Fluticasone Propionate	Completed	AstraZeneca	Phase 3	2003-04-01	The purpose of this study is to compare once daily treatment with Rhinocort against placebo and Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.
NCT00641693 ↗	Assess the Efficacy and Safety of Rhinocort Aqua	Completed	AstraZeneca	Phase 2	2004-04-01	The purpose of this study is to compare Rhinocort with placebo in pediatric subjects aged 2-5 years with allergic rhinitis to study effects on nasal symptoms such as sneezing, runny and stuffy noses.

Clinical Trial Conditions for RHINOCORT

Condition Name

Condition Name for RHINOCORT
Intervention	Trials
Seasonal Allergic Rhinitis	4
Allergic Rhinitis	2
Allergic Conjunctivitis	1
Sinus Infection	1

Condition MeSH

Condition MeSH for RHINOCORT
Intervention	Trials
Rhinitis	9
Rhinitis, Allergic	7
Rhinitis, Allergic, Seasonal	5
Conjunctivitis, Allergic	1

Clinical Trial Locations for RHINOCORT

Trials by Country

Trials by Country for RHINOCORT
Location	Trials
United States	9
Canada	3
China	3
Thailand	1
Austria	1

Trials by US State

Trials by US State for RHINOCORT
Location	Trials
Wisconsin	1
Washington	1
Virginia	1
Pennsylvania	1
Maryland	1

Clinical Trial Progress for RHINOCORT

Clinical Trial Phase

Clinical Trial Phase for RHINOCORT
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	3
Phase 2	5

Clinical Trial Status

Clinical Trial Status for RHINOCORT
Clinical Trial Phase	Trials
Completed	10
Recruiting	1
Withdrawn	1

Clinical Trial Sponsors for RHINOCORT

Sponsor Name

Sponsor Name for RHINOCORT
Sponsor	Trials
AstraZeneca	4
Ligand Pharmaceuticals	2
Medstar Health Research Institute	1

Sponsor Type

Sponsor Type for RHINOCORT
Sponsor	Trials
Other	13
Industry	10
NIH	1

Last updated: February 6, 2026

What Are the Latest Clinical Trial Developments for Rhinocort?

Rhinocort, primarily known as budesonide nasal spray, continues to undergo research to expand its applications. Recent trials focus on alternative delivery methods and new indications, although no large-scale Phase III studies are explicitly reported in the past year.

Recent Clinical Trials Data:

• The U.S. National Library of Medicine lists ongoing or recently completed studies related to Rhinocort (budesonide nasal spray), primarily targeting allergic rhinitis and nasal polyposis.
• As of 2023, no new registration trials have been added to ClinicalTrials.gov regarding Rhinocort; most are observational or post-marketing studies.
• Past key trials demonstrated efficacy in allergic rhinitis, with symptom reduction comparable to other intranasal corticosteroids.

Key Takeaway:

The firm focus in clinical development remains on marketing support rather than new indication discovery. The lack of recent large-scale trials suggests limited near-term pipeline expansion.

How Does Rhinocort Perform in Current Market Conditions?

Rhinocort belongs to the intranasal corticosteroids segment, a mature market in allergy treatment. It is marketed globally, including in the U.S., Europe, and emerging markets.

Market Share and Position:

• In 2022, Rhinocort generated approximately $500 million worldwide.
• The drug holds roughly 10-15% market share in the U.S. allergic rhinitis segment, competing mainly with Flonase (fluticasone propionate), Nasacort (triamcinolone acetonide), and Ayr (beclomethasone).
• Its primary advantage is a well-established safety profile and presence in pediatric formulations.

Pricing and Reimbursement:

• Retail price in the U.S. averages around $25 per 120-dose spray.
• Insurance coverage is generally broad, but formulary tier placement affects patient out-of-pocket costs.

Market Dynamics:

• Growth driven by increasing prevalence of allergic rhinitis (estimated at 20-30% globally).
• Competition from newer, non-steroidal therapies such as antihistamines and biologics in certain indications.
• Patent expiry dates are approaching; the U.S. patent expired in 2018, with some formulations still under patent till 2024, enabling generic competition.

What Are the Market Projections for Rhinocort Through 2030?

The forecast for Rhinocort’s market is shaped by demographic trends, regulatory developments, and competitive landscape shifts.

Market Size Predictions:

• The global allergic rhinitis market was valued at approximately $8 billion in 2022.
• It is expected to grow at a compound annual growth rate (CAGR) of 4% through 2030, reaching nearly $11.7 billion.
• Rhinocort’s market share may decline modestly from current levels due to generic entry but could be offset by expanding indications and regional penetration.

Forecast Scenarios:

Year	Estimated Market Size	Rhinocort Share	Projected Revenue (approx.)
2023	$8 billion	10-15%	$800 million - $1.2 billion
2025	$9.2 billion	8-12%	$736 million - $1.1 billion
2030	$11.7 billion	7-10%	$819 million - $1.17 billion

Key Factors Influencing Outlook:

• Entry of generics reducing prices and margins.
• Approval for new indications, such as nasal polyposis or chronic rhinosinusitis.
• Regional expansion into Asia-Pacific and Latin America.

How Do Regulatory Changes Affect Rhinocort?

Regulatory authorities continue to approve off-label uses based on emerging evidence, but official label changes are limited.

• The FDA approved Rhinocort for pediatric use in children as young as 6 months.
• EMA approvals align with these indications, with additional regional variations.

Patent protections for certain formulations will expire between 2024 and 2026, opening markets for generics, which typically reduce originator revenue by up to 80%.

What Are the Key Strategic Considerations for Stakeholders?

• patent expirations pressurize pricing and market share.
• A potential shift toward combination therapies (e.g., nasal steroids with antihistamines) could influence demand.
• Regional growth strategies depend on regulatory pathways and local competition.

Key Takeaways

• Clinical development for Rhinocort remains focused on label maintenance and minor enhancements rather than new indications.
• The drug holds a stable position in the allergic rhinitis segment, with limited growth expected due to generic competition.
• The global market for allergy treatments is expanding, but Rhinocort’s market share may diminish unless it adapts to competitive pressures or expands indications.
• Patent expirations and increasing regional penetration shape future growth prospects.
• Regulatory approvals for pediatric use and potential indication expansion could support revenue stability.

FAQs

1. Are there any new formulations of Rhinocort in development?
Current information shows no significant new formulations in late-stage development. Most innovation efforts focus on optimizing existing delivery methods or expanding indications.

2. How does Rhinocort compare to other intranasal corticosteroids?
It offers comparable efficacy with a long-standing safety profile. It is generally less expensive than some newer agents but faces pricing pressure from generics.

3. When will generic versions of Rhinocort become available?
Generic versions are expected to become available by 2024-2026 following patent expiries, which could significantly impact revenues.

4. What regional markets offer growth opportunities for Rhinocort?
Emerging markets in Asia-Pacific and Latin America present growth potential due to rising allergy prevalence and expanding healthcare access.

5. What are the main challenges facing Rhinocort’s market share?
Patent expiration, competition from generics, and newer therapies such as biologics pose risks to market share stability.

References

1. ClinicalTrials.gov. "Rhinocort clinical trials." Accessed March 2023.
2. IQVIA. "Global Pharmacoverview 2022."
3. Evaluate Pharma. "Forecast: Allergic Rhinitis Market 2022-2030," 2022.
4. U.S. FDA. “Approved Drug Products with Therapeutic Equivalence Evaluations,” 2023.
5. European Medicines Agency. “Marketing authorization approvals,” 2023.